4D Molecular Therapeutics Inc
NASDAQ:FDMT

Watchlist Manager
4D Molecular Therapeutics Inc Logo
4D Molecular Therapeutics Inc
NASDAQ:FDMT
Watchlist
Price: 9.21 USD -20.05%
Market Cap: 526.3m USD

Relative Value

The Relative Value of one FDMT stock under the Base Case scenario is 4.07 USD. Compared to the current market price of 9.21 USD, 4D Molecular Therapeutics Inc is Overvalued by 56%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

FDMT Relative Value
Base Case
4.07 USD
Overvaluation 56%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
17
vs Industry
1
Median 3Y
413.2
Median 5Y
130.1
Industry
7.9
Forward
66.8
vs History
vs Industry
Median 3Y
-6.4
Median 5Y
-8.4
Industry
23.7
Forward
-2.5
vs History
vs Industry
Median 3Y
-10.1
Median 5Y
-11.2
Industry
22
vs History
vs Industry
Median 3Y
-9.7
Median 5Y
-10
Industry
23.8
vs History
75
vs Industry
73
Median 3Y
2
Median 5Y
2.4
Industry
3.3
vs History
8
vs Industry
53
Median 3Y
37.6
Median 5Y
55.5
Industry
8.3
Forward
28.1
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
vs History
vs Industry
17
Median 3Y
-2.9
Median 5Y
-4.2
Industry
6.4
Forward
-1
vs History
vs Industry
15
Median 3Y
-2.8
Median 5Y
-5.4
Industry
7
Forward
-1
vs History
vs Industry
18
Median 3Y
-5.2
Median 5Y
-7.7
Industry
8.3
vs History
vs Industry
14
Median 3Y
-5.1
Median 5Y
-6.9
Industry
6.5
vs History
75
vs Industry
46
Median 3Y
7.8
Median 5Y
8.8
Industry
5.7

Multiples Across Competitors

FDMT Competitors Multiples
4D Molecular Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
4D Molecular Therapeutics Inc
NASDAQ:FDMT
526.3m USD 4 385.5 -2.5 -1 -1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 786 100.8 -160 580.3 -194 995.7 -192 770.6
US
Abbvie Inc
NYSE:ABBV
397.8B USD 6.7 169.4 16.4 23.3
US
Amgen Inc
NASDAQ:AMGN
175.2B USD 4.9 25 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
150.7B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.4B USD 9.8 31.1 22.8 23.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 085.2 -532.1 -579.4 -563.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.6B USD 5.5 17.1 16.3 18.5
AU
CSL Ltd
ASX:CSL
84.2B AUD 3.6 18.5 12.5 15.6
NL
argenx SE
XBRU:ARGX
44.5B EUR 14.5 34.1 58.8 60.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.1B USD 16.2 1 195.5 157 190.4
P/E Multiple
Earnings Growth PEG
US
4D Molecular Therapeutics Inc
NASDAQ:FDMT
Average P/E: 188.7
Negative Multiple: -2.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 580.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
169.4
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
9%
1.9
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
NL
argenx SE
XBRU:ARGX
34.1
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 195.5
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
4D Molecular Therapeutics Inc
NASDAQ:FDMT
Average EV/EBITDA: 39.3
Negative Multiple: -1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 995.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.4
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.8
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.3
11%
1.5
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
NL
argenx SE
XBRU:ARGX
58.8
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
157
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
4D Molecular Therapeutics Inc
NASDAQ:FDMT
Average EV/EBIT: 45.3
Negative Multiple: -1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 770.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.3
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.8
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
13%
1.4
AU
CSL Ltd
ASX:CSL
15.6
11%
1.4
NL
argenx SE
XBRU:ARGX
60.4
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
190.4
N/A N/A